Омезол

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Омезол

What is Омезол?

Омезол is a pharmacological agent belonging to the class of medications known as proton pump inhibitors (PPIs). It is primarily utilized to manage conditions associated with excessive gastric acid production. By targeting the final stage of acid secretion, the medication helps in the healing of the gastrointestinal mucosa and provides relief from symptoms caused by acid-related disorders.

Mechanism of Action

The active component in Омезол works by specifically inhibiting the H^+/K^+-ATPase enzyme system, commonly referred to as the "proton pump," located within the parietal cells of the stomach lining. This action results in a significant reduction of both basal and stimulated gastric acid secretion, regardless of the stimulus. The suppression of acid creates an environment conducive to the recovery of the esophagus and stomach lining.

Therapeutic Indications

Омезол is commonly used in clinical practice for several gastrointestinal conditions, including:

  • Gastroesophageal Reflux Disease (GERD): To manage the symptoms of acid reflux and treat erosive esophagitis.
  • Peptic Ulcer Disease: To aid in the healing of gastric and duodenal ulcers.
  • Zollinger-Ellison Syndrome: To manage pathological hypersecretory conditions where the stomach produces extreme amounts of acid.
  • Eradication of Helicobacter pylori: Used as part of a combination regimen with antibiotics to treat infections associated with peptic ulcers.

General Characteristics

As a systemic medication, its effects are dose-dependent and reversible. It is typically formulated to be acid-resistant, ensuring that the medication passes through the stomach and is absorbed in the small intestine to reach its target site via the bloodstream. While it reduces the acidity of the stomach, it does not affect the motility of the gastrointestinal tract.

What side effects are possible with Омезол?

Possible Side Effects and Safety Information

The safety profile of Omeprazole is classified according to the frequency and the System-Organ Class (SOC) affected, as documented in official regulatory sources. These classifications distinguish between frequent, expected reactions and rare, serious adverse events.


Adverse Reaction Frequencies

Adverse reactions are grouped by incidence based on regulatory reporting standards:

  • Common: The most frequently reported adverse reactions include headache and a range of gastrointestinal effects such as abdominal pain, diarrhea, constipation, flatulence, and nausea/vomiting.
  • Uncommon: Effects documented as uncommon include dizziness, insomnia, dermatitis, rash, pruritus, and increased liver enzyme levels.
  • Rare/Very Rare: Rare effects include various Blood and Lymphatic System Disorders (e.g., leukopenia, agranulocytosis), Hypersensitivity Reactions (e.g., angioedema), and Acute Interstitial Nephritis.

Serious Adverse Reactions and Safety Patterns

The regulatory label explicitly lists serious reactions, including Severe Cutaneous Adverse Reactions (SCARs), such as Stevens-Johnson syndrome (SJS), and Anaphylaxis.

A key safety pattern noted is the association between long-term use and specific risks. Prolonged use is linked to an increased risk of bone fractures (hip, wrist, or spine) and Hypomagnesemia, which is an electrolyte imbalance that can be severe.

Population-specific safety notes caution in patients with severe hepatic impairment due to altered exposure to the medicine. Omeprazole's mechanism also creates a safety restriction by altering gastric acidity, which can affect the absorption of certain co-administered pH-dependent drugs.

Overdose and Emergency Response

Overdose and When to Seek Help

The information below is based strictly on regulatory guidance regarding documented Omeprazole overdosage and required emergency actions.

Documented Overdose Manifestations

Official prescribing information documents overdose exposures, sometimes involving doses up to 900 mg. The clinical presentation is typically described as transient and variable. Symptoms reported in these cases include nausea, vomiting, somnolence (drowsiness), headache, confusion, diaphoresis (increased sweating), flushing, and tachycardia (fast heart rate).

Regulatory documentation states that no serious clinical outcome has been reported in connection with documented overdosage up to this high dose level.

Emergency Actions and Management

Immediate medical help must be sought for any known or suspected overdosage. The regulator-mandated action is to seek emergency medical attention immediately, such as contacting a Poison Control Centre or going to the nearest emergency room.

Treatment is defined as symptomatic and supportive. The regulatory documents confirm that no specific antidote is known for Omeprazole. Furthermore, due to the substance being extensively protein bound, it is not readily dialyzable, meaning procedures like hemodialysis are unlikely to be effective. Supportive measures, including monitoring of vital signs, are the focus of official management.

Therapeutic Uses of Омезол

What Омезол Treats: Main Uses and Benefits

Омезол is a medication belonging to the class of proton pump inhibitors (PPIs). Its primary function is to reduce the production of stomach acid by inhibiting the enzyme system in the stomach lining responsible for acid secretion. This reduction in acidity helps manage various gastrointestinal conditions and allows the digestive tract to heal.

Main Therapeutic Uses

Омезол is commonly used to treat several conditions related to excessive gastric acid:

  • Gastroesophageal Reflux Disease (GERD): This condition occurs when stomach acid flows back into the esophagus, causing irritation and heartburn. Омезол helps alleviate these symptoms and prevents further damage to the esophageal lining.
  • Gastric and Duodenal Ulcers: The medication is used to treat active ulcers in the stomach or the upper part of the small intestine (duodenum). By lowering acid levels, it creates an environment conducive to the healing of the mucosal lining.
  • Zollinger-Ellison Syndrome: This is a rare condition characterized by the formation of tumors in the pancreas or duodenum that stimulate the overproduction of stomach acid. Омезол is used to manage the resulting high levels of acidity.
  • Erosive Esophagitis: For patients whose esophagus has been physically damaged by acid reflux, this medication helps repair the inflammation and tissue erosion.

Secondary Uses and Prevention

Beyond treating active conditions, Омезол may be utilized in specific clinical scenarios to prevent future complications:

  • Ulcer Prevention: It may be used to reduce the risk of developing stomach ulcers in individuals who require long-term treatment with non-steroidal anti-inflammatory drugs (NSAIDs).
  • Combination Therapy for H. pylori: In cases where ulcers are caused by Helicobacter pylori bacteria, Омезол is often used alongside antibiotics. The reduction in acid increases the effectiveness of the antibiotics and promotes ulcer healing.

Benefits of Treatment

The primary benefit of Омезол is the sustained control of gastric pH levels. By maintaining a less acidic environment, the medication provides:

  • Symptom Relief: Effective reduction of persistent heartburn, acid regurgitation, and upper abdominal pain.
  • Tissue Recovery: Facilitation of the natural healing process for damaged gastric and esophageal tissues.
  • Complication Reduction: Lowering the likelihood of severe complications such as gastrointestinal bleeding or strictures caused by chronic acid exposure.

Eligibility and Restrictions for Use

Who Can and Cannot Use Omeprazole

Official regulatory documents strictly define the patient populations eligible for Omeprazole. The medicine is absolutely contraindicated in patients with a known hypersensitivity to omeprazole, to other substituted benzimidazoles, or to any component of the formulation. Additionally, co-administration with the antiretroviral drugs nelfinavir or rilpivirine is formally prohibited.


Age and Conditional Eligibility

Omeprazole use is established for adults and for specific pediatric indications. The minimum eligible age is one month for the short-term treatment of erosive esophagitis, while use for GERD and maintenance therapy is approved for children one year and older. Safety and efficacy are officially not established for infants younger than one month of age.

Patients with impaired hepatic function require caution, and regulators advise that a dose adjustment should be considered due to altered metabolism. Conversely, no dose adjustment is necessary for those with impaired renal function. For patients with a gastric ulcer, malignancy must be excluded before beginning therapy. Omeprazole is not explicitly contraindicated during pregnancy or lactation, with use assessed on a benefit-risk basis.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The regulatory profile for Omeprazole (Омезол) details interactions arising primarily from two pharmacokinetic mechanisms: inhibition of the CYP2C19 enzyme and the resulting alteration of gastric pH.

Mandatory Restrictions and Prohibitions

Category Interacting Substance Regulatory Constraint
Contraindicated Rilpivirine, Nelfinavir Use is strictly prohibited due to significant reduction in antiretroviral plasma concentrations.
Avoided Clopidogrel Avoid concomitant use as Omeprazole diminishes anti-platelet activity via CYP2 C19 inhibition.
Avoided St John's Wort Co-administration should be avoided due to the potential for a reduction in Omeprazole concentration.

Clinically Significant Exposure Alteration

Omeprazole's CYP2 C19 inhibition results in the prolonged elimination and increased systemic exposure of substrates such as Warfarin and Diazepam. Separation is required for certain laboratory procedures, as Omeprazole must be withheld for at least 14 days prior to Chromogranin A ( CgA) diagnostic testing to avoid false positive results. pH-dependent absorption effects mandate caution with substances like Atazanavir and antifungals (e.g., Ketoconazole), as Omeprazole reduces their absorption and subsequent exposure. Additionally, Omeprazole may elevate the serum concentrations of Methotrexate and Digoxin.

Mechanism of Action

The mechanism of action for Омезол (Omeprazole) is defined by its ability to achieve irreversible inhibition of the enzyme system responsible for the final step of acid production. This action leads to a sustained and profound suppression of gastric acidity.

Permanent Inactivation of the Gastric Proton Pump

This mechanism acts on the H+/ K+-ATPase enzyme system—the Gastric Proton Pump—located in the parietal cells. Omeprazole is converted into an active chemical form that covalently and permanently binds to the pump, functionally suppressing the transport of hydrogen ions ( H+) into the stomach lumen. This specific interaction with the final common pathway of acid secretion results in a significant reduction of intragastric acidity.

⏳ Activity-Dependent Action and Sustained Effect

The mechanism is activity-dependent, meaning the drug must encounter the acidic environment present only within actively secreting cells to become activated and bind to the enzyme. Because the enzyme is permanently disabled, acid production only recovers when the parietal cell synthesizes and inserts new proton pumps. This process, which takes time, dictates the long duration of the drug's effect and the progressive increase in the degree of sustained suppression of acid transport over the initial doses.

Dosage and Administration Information

The administration of Omeprazole (Омезол) is governed by established protocols to ensure the medicine's integrity and proper delivery. The drug is available for two routes of administration: Oral (as delayed-release capsules or suspension) and Intravenous (IV) (as an injection or infusion), which is utilized when oral administration is not feasible. The typical dosing schedule for most common conditions ranges from 20 mg to 40 mg, generally taken once daily. However, specific protocols, such as H. pylori eradication or the management of pathological hypersecretory conditions, may require administration twice daily or higher total doses, sometimes reaching 360 mg per day in divided amounts.

Standardized procedures involve specific steps for oral intake. The delayed-release capsules or tablets must be swallowed whole with water and must not be crushed, chewed, or opened. This restriction is necessary because the active compound is acid-labile and requires the enteric coating to pass safely through the stomach for absorption. The timing of administration is also a factor: oral forms are generally taken at least one hour before a meal to optimize the drug’s effectiveness.

For patients with hepatic impairment, guidelines recommend a dose adjustment, typically a maximum daily dose of 20 mg due to reduced drug clearance. If the IV route is utilized, the drug requires specific reconstitution and is administered as an infusion over 20 to 30 minutes. These instructions define the framework for appropriate use.

Recent Clinical Evidence

Research evidence / Overview of Studies for Омезол

The evidence base for Omeprazole (Омезол) relies primarily on findings from Randomized Controlled Trials (RCTs) and subsequent systematic reviews. This evidence is used by regulatory bodies to describe what the medication was studied for and what has been observed so far, without giving clinical advice or making personal predictions.


Evidence Structure for Gastroesophageal Reflux Disease (GERD)

Research includes short-term RCTs comparing Omeprazole to a placebo or other specified treatments. These studies were studied for individuals experiencing conditions characterized by fluctuating or episodic manifestations, such as frequent heartburn and acid regurgitation. Researchers monitored patient-reported outcomes describing perceived discomfort. Trials described different measurements of symptom change compared to placebo during the short-term study periods.

Evidence for Healing of Erosive Esophagitis and Ulcers

For erosive esophagitis, studies research examined mucosal damage associated with acid reflux. These clinical trials relied on specialized imaging tools (endoscopy) to confirm damage before and following treatment. The primary measure was the endoscopic assessment of mucosal integrity. Separately, Omeprazole was evaluated in short-term RCTs for the management of active duodenal and benign gastric ulcers in adult populations. Findings describe patterns observed in studies, which included measurements of changes in mucosal integrity within the specified short-term follow-up periods.

Research on Helicobacter Pylori Eradication and Uncertainties

Omeprazole was evaluated in multi-drug regimens in RCTs for H. pylori in adult patients. Studies research examined the outcomes when Omeprazole was combined with specific antibiotics for the bacteria. The measured outcome of the regimen was defined by a specific test performed four weeks after the treatment ended. While a large amount of evidence exists, the research highlights what is known and what is still uncertain. Long-term effects are not fully established by the high level of certainty provided by long-running RCTs, and evidence is limited regarding the long-term changes in symptoms after the medication is stopped.

Key Studies & References

  1. MedlinePlus Drug Information: Omeprazole

Frequently Asked Questions (FAQ)

Common questions about Омезол (FAQ)


Q: How quickly can I expect to notice the effect of Омезол?

A: Official information indicates that this medicine typically begins reducing stomach acid within a few hours of the first dose. However, achieving the full therapeutic benefit for the condition being treated may require 1 to 4 days of continuous use.


Q: Is Омезол the same kind of medicine as Famotidine or Cimetidine?

A: No, Omeprazole is classified as a Proton Pump Inhibitor (PPI). This class works by irreversibly blocking the final stage of acid production in the stomach. Medicines like Famotidine or Cimetidine belong to a different class called H2 receptor blockers, which work in a distinct way to reduce acid.


Q: Is it safe to take Омезол with antibiotics?

A: Regulatory documents confirm that Omeprazole is included as part of specific, approved combination drug regimens with certain antibiotics to treat H. pylori infection. Regulatory labeling indicates that a review of the risks associated with the individual antibiotics used in the combination is necessary.


Q: Can I take pain relievers like ibuprofen while using Омезол?

A: The official indications for Omeprazole include the prevention and treatment of ulcers and damage associated with the use of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs). This indication describes Omeprazole's use in managing certain gastrointestinal issues that may arise during the use of NSAIDs.


Q: Can Омезол be split or crushed if someone has trouble swallowing pills?

A: Official instructions for the delayed-release capsules or tablets strictly mandate that they must be swallowed whole and should not be crushed, split, or chewed. This restriction is in place because the medicine relies on this coating to bypass the acidic stomach environment for proper function and absorption.


Q: Does taking Омезол cause weight gain?

A: Weight gain is not listed among the common adverse reactions reported during clinical trials. Reports from post-marketing surveillance and studies examining long-term use have suggested a possible association. However, this is not a universally listed common side effect.


Q: Can I take Омезол if I am already taking supplements or vitamins?

A: Official information describes that, like other acid-blocking medicines, long-term therapy with Omeprazole may potentially reduce the body’s absorption of Vitamin B12 (cyanocobalamin). Specific interactions with a broad range of other supplements or vitamins are not generally detailed in the official product information.


Q: Does Омезол contain gluten or lactose?

A: The official prescribing information for Omeprazole lists all inactive ingredients and excipients, which can be found in the Description section of the label. This exact list can vary depending on the specific manufacturer and formulation (such as capsule or tablet).


Q: Is Омезол available without a prescription in some countries?

A: Yes, in several countries, a specific 20 mg delayed-release formulation of omeprazole is available for non-prescription (Over-The-Counter or OTC) use for the short-term treatment of frequent heartburn.


Q: How long does the effect of a single dose of Омезол typically last?

A: The drug’s mechanism is designed to provide sustained acid suppression. Therefore, it is typically administered once a day, reflecting an effect that generally lasts for up to 24 hours.


Q: Can Omeprazole be used for a short period, like just a few days?

A: The regulatory indications define short-term treatment durations depending on the condition. For example, symptomatic GERD treatment is typically defined as up to four weeks, and the non-prescription version is limited to a 14-day course.


Q: Is the research on Омезол mostly from recent years or older studies?

A: Omeprazole was patented in the late 1970s and was approved for medical use in 1988. As such, the evidence base includes both foundational, older clinical trials and more recent systematic reviews.


Q: Is there any difference between the brand name and generic versions of Омезол?

A: Regulatory agencies, such as the FDA, require generic versions of omeprazole to demonstrate that they are bioequivalent to the brand-name product. Bioequivalence means they deliver the same amount of the active ingredient into the bloodstream over the same period of time.


Q: Is there a maximum duration of use for Омезол mentioned in official documents?

A: The defined treatment duration varies by condition. While most short-term uses are limited to 4 to 8 weeks, the medicine is also officially indicated for the long-term management of specific conditions where the stomach produces too much acid, such as Zollinger-Ellison Syndrome.


Q: Are there any known long-term effects on the stomach lining from Омезол?

A: Official warnings and precautions note that Atrophic Gastritis (inflammation of the stomach lining) has been observed in some individuals with long-term use. Additionally, benign growths called fundic gland polyps have also been reported, primarily with prolonged use.


Q: Can Омезол interfere with lab tests, besides those for the liver?

A: Yes, Omeprazole is known to interfere with the diagnostic test for Chromogranin A ( CgA), which is used to detect certain tumors. Regulatory documents require the medicine to be withheld for at least 14 days before this specific test is performed.


Q: What happens if I accidentally take two doses of Омезол close together?

A: Official information regarding accidental overdosage states that effects have been variable and generally benign. Official documentation notes that ingestion exceeding the prescribed amount warrants consulting a healthcare professional or poison control center.


Q: Does the use of Омезол have any known effect on mood or sleep?

A: Official adverse reaction lists include effects that may relate to mood or sleep. Insomnia (difficulty sleeping) is listed as an uncommon reaction, and post-marketing surveillance reports have included instances of agitation, confusion, or depression.


Q: Why is Омезол sometimes prescribed alongside NSAIDs?

A: Omeprazole is indicated for the prevention and treatment of ulcers, duodenal ulcers, and erosions associated with the use of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs). It is often co-prescribed to manage the potential gastrointestinal risks.


Q: Does Omeprazole affect the absorption of other non-acid-related medicines?

A: Yes, Omeprazole is documented as an inhibitor of the liver enzyme CYP2C19. This can result in increased systemic exposure or slower elimination of other medicines that are processed by this same enzyme, such as certain blood thinners or anti-anxiety medications.

How should Омезол be stored and disposed of?

Storage and Disposal Conditions for Omeprazole

Omeprazole delayed-release products must be stored at controlled room temperature, specifically 20 C to 25 C (68 F to 77 F). The medicine must be kept in its original container and be protected from moisture. Storage must ensure the product is kept out of the sight and reach of children.


Stability and Handling

If the medication is mixed with a food substance or liquid for administration, that mixture must not be stored for later use; it should be used immediately.


Disposal Requirements

Unused or expired Omeprazole must be disposed of according to local requirements. The product should not be disposed of via household trash or wastewater unless specifically instructed by regulatory bodies.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Омезол found in:

A-Z Index: